276 related articles for article (PubMed ID: 37175571)
1. A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.
Korb VG; Schultz IC; Beckenkamp LR; Wink MR
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175571
[TBL] [Abstract][Full Text] [Related]
2. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.
Dos Anjos F; Simões JLB; Assmann CE; Carvalho FB; Bagatini MD
J Immunol Res; 2020; 2020():8632048. PubMed ID: 33299899
[TBL] [Abstract][Full Text] [Related]
3. Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.
Shafaghat Z; Ghomi AK; Khorramdelazad H; Safari E
Inflammopharmacology; 2023 Dec; 31(6):3005-3020. PubMed ID: 37805959
[TBL] [Abstract][Full Text] [Related]
4. Possible role of purinergic signaling in COVID-19.
Franciosi MLM; Lima MDM; Schetinger MRC; Cardoso AM
Mol Cell Biochem; 2021 Aug; 476(8):2891-2898. PubMed ID: 33740184
[TBL] [Abstract][Full Text] [Related]
5. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
[TBL] [Abstract][Full Text] [Related]
6. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Lécuyer D; Nardacci R; Tannous D; Gutierrez-Mateyron E; Deva Nathan A; Subra F; Di Primio C; Quaranta P; Petit V; Richetta C; Mostefa-Kara A; Del Nonno F; Falasca L; Marlin R; Maisonnasse P; Delahousse J; Pascaud J; Deprez E; Naigeon M; Chaput N; Paci A; Saada V; Ghez D; Mariette X; Costa M; Pistello M; Allouch A; Delelis O; Piacentini M; Le Grand R; Perfettini JL
Front Immunol; 2023; 14():1270081. PubMed ID: 37920468
[TBL] [Abstract][Full Text] [Related]
7. Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.
Nadeali Z; Mohammad-Rezaei F; Aria H; Nikpour P
Life Sci; 2022 May; 297():120482. PubMed ID: 35288174
[TBL] [Abstract][Full Text] [Related]
8. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
[TBL] [Abstract][Full Text] [Related]
9. High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.
da Silva GB; Manica D; da Silva AP; Kosvoski GC; Hanauer M; Assmann CE; Simões JLB; Pillat MM; de Lara JD; Marafon F; Bertollo AG; Mingoti MED; Gavioli J; Réus GZ; de Oliveira GG; Ignácio ZM; Bagatini MD
J Mol Med (Berl); 2022 Apr; 100(4):645-663. PubMed ID: 35249135
[TBL] [Abstract][Full Text] [Related]
10. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
Zarei M; Sahebi Vaighan N; Ziai SA
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
[TBL] [Abstract][Full Text] [Related]
11. Extracellular creatine kinase may modulate purinergic signalling.
Brewster LM
Purinergic Signal; 2020 Sep; 16(3):305-312. PubMed ID: 32572751
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of P2X7 Purinergic Receptor Modulation in the Main Organs Affected by the COVID-19 Cytokine Storm.
Batista Simões JL; Sobierai LD; Pereira SM; Rodrigues Dos Santos MV; Bagatini MD
Curr Pharm Des; 2022; 28(22):1798-1814. PubMed ID: 35838210
[TBL] [Abstract][Full Text] [Related]
13. Purinergic signaling elements are correlated with coagulation players in peripheral blood and leukocyte samples from COVID-19 patients.
Schultz IC; Bertoni APS; Wink MR
J Mol Med (Berl); 2022 Apr; 100(4):569-584. PubMed ID: 35091759
[TBL] [Abstract][Full Text] [Related]
14. Extracellular nucleotides and nucleosides as signalling molecules.
Giuliani AL; Sarti AC; Di Virgilio F
Immunol Lett; 2019 Jan; 205():16-24. PubMed ID: 30439478
[TBL] [Abstract][Full Text] [Related]
15. Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines.
Morrone FB; Jacques-Silva MC; Horn AP; Bernardi A; Schwartsmann G; Rodnight R; Lenz G
J Neurooncol; 2003 Sep; 64(3):211-8. PubMed ID: 14558596
[TBL] [Abstract][Full Text] [Related]
16. The role of Pannexin-1 channels, ATP, and purinergic receptors in the pathogenesis of HIV and SARS-CoV-2.
Hernandez CA; Eugenin EA
Curr Opin Pharmacol; 2023 Dec; 73():102404. PubMed ID: 37734241
[TBL] [Abstract][Full Text] [Related]
17. Purinergic receptors: new targets for the treatment of gout and fibrosis.
Gicquel T; Le Daré B; Boichot E; Lagente V
Fundam Clin Pharmacol; 2017 Apr; 31(2):136-146. PubMed ID: 27885718
[TBL] [Abstract][Full Text] [Related]
18. Purinergic signalling in host innate immune defence against intracellular pathogens.
Coutinho-Silva R; Savio LEB
Biochem Pharmacol; 2021 May; 187():114405. PubMed ID: 33406411
[TBL] [Abstract][Full Text] [Related]
19. Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium.
Bergamin LS; Braganhol E; Figueiró F; Casali EA; Zanin RF; Sévigny J; Battastini AM
J Cell Biochem; 2015 May; 116(5):721-9. PubMed ID: 25546398
[TBL] [Abstract][Full Text] [Related]
20. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
